Rho Chi Post

An award-winning, electronic, student-operated newsletter publication by the St. John's University College of Pharmacy and Health Sciences Rho Chi Beta Delta chapter

Menu

Skip to content
  • Home
  • Issues
    • Current Issue
    • All Issues
  • Articles
    • Featured
    • In the News / Politics
    • Events
    • Clinical
    • Advice / Opinions
    • Puzzles
    • Recently in PubMed
  • For Authors
    • Author Guidelines
    • AMA Citation Generator
    • Sign Up for Article(s)
    • Suggest Article(s)
    • Submit Article(s)
    • Check Statuses
    • Cite Your Article
  • About Us
    • About the Rho Chi Post
    • The Editorial Team
  • Apply for a Position
  • Subscribe
  • Login

Tag Archives: tablets

Tailored Tablets...
August 1, 2014 - Featured , In the News / Politics

By: Azia Tariq, Staff Editor – Truly personalized medication is the goal of researchers in the pharmaceutical and biotechnological industries. For example, when a patient requires a precise dose that is not manufactured as a tablet, the tablet will be broken up in order to deliver the dose as close as possible. Not only is…

Riociguat (Adempas®) New Drug for Pulmonary Hypertens...
April 1, 2014 - Clinical , Featured

By: Hayeon Na, Co-Copy Editor [Content-Focused] – On October 8th of 2013, Bayer’s new drug riociguat (Adempas®) was approved for the treatment of patients whose pulmonary hypertension (PH) belongs in WHO groups 1 and 4.1 Riociguat (Adempas®) is a soluble guanylate cyclase (sGC) stimulator, and currently the only one of its kind on the market.…

Low Literacy and Medication Management?...
February 1, 2014 - Professional Advice / Opinions

By: Jenny Park, Pharm. D. Candidate c/o 2015 – As the Affordable Care Act brings health care to many people who are currently uninsured, healthcare providers should expect an increase in the number of patients who don’t understand their plan, disease states, and medications. Health literacy is defined as “the degree to which individuals have…

Ketoconazole No More...
October 1, 2013 - Featured , In the News / Politics

By: Hayeon Na, Co-Copy Editor [Content-Focused] – The Food and Drug Administration (FDA) announced on July 26th that oral dosage forms of ketoconazole (Nizoral®) should no longer be prescribed as first-line therapy for any fungal infections.1 The label and indication for oral ketoconazole were updated, and a new medication guide was added. Other dosage forms…

Canagliflozin (Invokana®): New Type 2 Diabetes Drug...
October 1, 2013 - Clinical

By: Sang Hyo Kim, Staff Editor – On March 29th 2013, the U.S Food and Drug Administration approved canagliflozin (Invokana®), a new form of a diabetic drug for patients with type 2 diabetes mellitus.1 Canagliflozin is in a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors and is the only oral, once-daily…

FDA Takes Major Strides Towards Opioid Abuse Prevention...
June 1, 2013 - Featured , In the News / Politics

By: Ada Seldin PharmD Candidate c/o 2015 – On April 16th, 2013, the FDA approved the labeling change for the reformulated OxyContin® (oxycodone hydrochloride controlled-release) tablets, made by Pharma L.P. This change reflects the abuse-deterrent properties of the reformulated OxyContin®, which were not present in the original formulation approved by the FDA in 1995. OxyContin®…

Ivacaftor (KalydecoTM): Targeting the Core of Cystic Fi...
November 1, 2012 - Clinical , Featured

By: Eugene Kolomiyets, PharmD Candidate c/o 2013, AMSCOP at LIU – Cystic fibrosis (CF) is an autosomal recessive disease caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene located on chromosome 7.1  The disease has been linked to thousands of possible mutations, but only as many as 25-30 are tested for…

Meet the new Beta 3 Agonist: Mirabegron (Myrbetriq®)...
August 1, 2012 - Clinical , Featured , In the News / Politics

By: Steve P. Soman – Mirabegron (Mybetriq®), known also by the brand name Betanis®in Japan, is a new once daily oral drug.   First in its class, it is a selective β(3)-adrenoceptor agonist that improves symptoms associated with over active bladder (OAB) such as urinary incontinence, urgency, and urinary frequency by enhancing storage function and relaxing…

Artificial Saliva Agents in Xerostomia...
July 1, 2012 - Clinical , Featured

By: Neal Shah, Co-Editor-in-Chief – Xerostomia, commonly known as dry mouth, is an anti-muscarinic side effect of numerous medications.  Antidepressants, analgesics, diuretics, and antihistamines have a high propensity to cause xerostomia.1  Xerostomia may also result from Sjogren’s syndrome, Parkinson’s disease, and various chemotherapy agents.2  Traditionally, muscarinic agonists like pilocarpine have been used to reverse xerostomia.…

Matching Challenge: Look-Alike, Sound-Alikes...
June 1, 2012 - Puzzles

By: Addolorata Ciccone, Pharm.D. Candidate c/o 2013 – The following medications are easily confused.  Try to match each one with its corresponding fun fact.  This capsule should be swallowed whole; if chewed or dissolved orally, oropharyngeal anesthesia may occur, which poses a choking hazard.  Drinking a glass of water can help bypass this potential adverse…

Being Aware of Pharmacy Security and Fraud...
May 1, 2012 - Featured , Professional Advice / Opinions

By: Sanjay Dave, Supervising Pharmacist, Class of 1985 St. John’s University College of Pharmacy and Allied Health Professions – Mr. Sanjay Dave is a St. John’s University College of Pharmacy and Allied Health Professions Graduate, Class of 1985.  Since graduation, he has worked for Pathmark Pharmacies and is currently the supervising pharmacist at Pathmark Pharmacy…

Jentadueto Approved by FDA for Type 2 Diabetes Mellitus...
March 1, 2012 - Clinical , In the News / Politics

By: Ebey P. Soman – The FDA recently approved a combination tablet of linagliptin with metformin hydrochloride (Jentadueto®) for the treatment of type 2 diabetes.  Developed by Boehringer Ingelheim and Eli Lilly, the new combination tablet provides a twice-daily treatment option for healthcare providers looking for greater flexibility in treating diabetes. Prescribers may add a…

The Latest Novartis Recalls...
February 1, 2012 - In the News / Politics

By: Aleena Chacko, Long Island University Pharm.D. Candidate c/o 2013 – Established in 1996, Novartis International AG is a multinational pharmaceutical company based in Switzerland.  On January 8, 2012, Novartis issued a recall on some popular over the counter (OTC) medications in the United States (U.S.) over concerns about broken or incorrect tablets ending up…

Hope on the Horizon: Chikungunya Vaccine Trial Begins!...
January 1, 2012 - Clinical , Featured , In the News / Politics

By: Ebey P. Soman – Since its discovery in Tanganyika (modern day Mozambique and Tanzania in Africa) in 1952, Chikungunya virus outbreaks have been documented in Africa, South Asia, and Southeast Asia.  Due to recent globalization and increased travel, infection has also spread outside of tropical regions and even into western nations (such as the…

The Future of Pharmacist Practice...
November 1, 2011 - Featured , Professional Advice / Opinions

By: Dr. Bernard Sorofman – Foreword: Dr. Bernard Sorofman is a pharmacy professor and Chair of Pharmacy Practice and Science, as well as the Executive Associate Dean at the College of Pharmacy for the University of Iowa. One of our student editors, Ebey P. Soman, had the privilege to attend and meet Dr. Sorofman at…

Faculty Spotlight: Dr. Abu Serajuddin...
November 1, 2011 - Featured , Professional Advice / Opinions

By: Ebey P. Soman – Dr. Abu Serajuddin is a true inspiration for student pharmacists who wish to enter the pharmaceutical industry setting. He attained his Bachelors of Pharmacy with honors at Dhaka University in Bangladesh and majored in Pharmaceutics to get his Master of Sciences degree at Columbia University in New York. He obtained…



Do You Want to be a Published Author? Submit your Article(s) Today!



Tweets by @RhoChiPost

HOME: Home Page

VOLUMES / ISSUES: 14 . 13 . 12 . 11 . 10 . 9 . 8 . 7 . 6 . 5 . 4 . 3 . 2 . 1

ARTICLES: Featured . In the News / Politics . Events . Clinical . Advice / Opinions . Puzzles

FOR AUTHORS: Guidelines . AMA Citation Generator . Sign Up . Suggest . Submit . Cite

ABOUT US: About the Rho Chi Post . The Editorial Team . Apply for a Position

SUBSCRIBE: Google Groups Email List


Copyright © 2011-2025 Rho Chi Post